Cardiovascular, renal, and endocrine response to atrial natriuretic peptide in angiotensin II mediated hypertension

Brooks Sayre Edwards, T. R. Schwab, R. S. Zimmerman, D. M. Heublein, N. S. Jiang, John C Jr. Burnett

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Studies done in vitro have demonstrated that atrial natriuretic peptide (ANP) antagonizes angiotensin II-mediated contraction of vascular smooth muscle. The present studies were designed to examine the in vivo actions of ANP in acute angiotensin II-mediated hypertension. The cardiovascular, renal, and hormonal effects of intravenous ANP were evaluated in anesthetized normotensive (n = 6) and hypertensive (n = 6) dogs. In both groups, ANP (3.0 μg/kg bolus, 0.3 μg/kg/min continuous infusion) reduced arterial pressure and cardiac output without changing systemic vascular resistance. ANP specifically reduced renal vascular resistance and increased sodium excretion. The natriuresis observed was greater in hypertensive than in normotensive dogs. This occurred without a significant change in glomerular filtration rate or aldosterone. The ANP-mediated reduction in arterial pressure was associated with an increase in circulating arginine vasopressin and catecholamines but not in renin. These studies demonstrate that (1) ANP-mediated hypotension results from a reduction in cardiac output without changing systemic vascular resistance, (2) ANP acts as a specific renal vasodilator, (3) ANP-mediated natriuresis can occur without alteration in glomerular filtration rate or aldosterone, and (4) ANP specifically inhibits the release of renin without inhibiting the release of other circulating vasocontrictors.

Original languageEnglish (US)
Pages (from-to)663-667
Number of pages5
JournalCirculation Research
Volume59
Issue number6
StatePublished - 1986

Fingerprint

Atrial Natriuretic Factor
Angiotensin II
Hypertension
Kidney
Vascular Resistance
Natriuresis
Aldosterone
Glomerular Filtration Rate
Renin
Cardiac Output
Arterial Pressure
Dogs
Arginine Vasopressin
Vasodilator Agents
Vascular Smooth Muscle
Hypotension
Catecholamines
Sodium

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Cardiovascular, renal, and endocrine response to atrial natriuretic peptide in angiotensin II mediated hypertension. / Edwards, Brooks Sayre; Schwab, T. R.; Zimmerman, R. S.; Heublein, D. M.; Jiang, N. S.; Burnett, John C Jr.

In: Circulation Research, Vol. 59, No. 6, 1986, p. 663-667.

Research output: Contribution to journalArticle

@article{e6f50407edad479699e0bc782a8156a7,
title = "Cardiovascular, renal, and endocrine response to atrial natriuretic peptide in angiotensin II mediated hypertension",
abstract = "Studies done in vitro have demonstrated that atrial natriuretic peptide (ANP) antagonizes angiotensin II-mediated contraction of vascular smooth muscle. The present studies were designed to examine the in vivo actions of ANP in acute angiotensin II-mediated hypertension. The cardiovascular, renal, and hormonal effects of intravenous ANP were evaluated in anesthetized normotensive (n = 6) and hypertensive (n = 6) dogs. In both groups, ANP (3.0 μg/kg bolus, 0.3 μg/kg/min continuous infusion) reduced arterial pressure and cardiac output without changing systemic vascular resistance. ANP specifically reduced renal vascular resistance and increased sodium excretion. The natriuresis observed was greater in hypertensive than in normotensive dogs. This occurred without a significant change in glomerular filtration rate or aldosterone. The ANP-mediated reduction in arterial pressure was associated with an increase in circulating arginine vasopressin and catecholamines but not in renin. These studies demonstrate that (1) ANP-mediated hypotension results from a reduction in cardiac output without changing systemic vascular resistance, (2) ANP acts as a specific renal vasodilator, (3) ANP-mediated natriuresis can occur without alteration in glomerular filtration rate or aldosterone, and (4) ANP specifically inhibits the release of renin without inhibiting the release of other circulating vasocontrictors.",
author = "Edwards, {Brooks Sayre} and Schwab, {T. R.} and Zimmerman, {R. S.} and Heublein, {D. M.} and Jiang, {N. S.} and Burnett, {John C Jr.}",
year = "1986",
language = "English (US)",
volume = "59",
pages = "663--667",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Cardiovascular, renal, and endocrine response to atrial natriuretic peptide in angiotensin II mediated hypertension

AU - Edwards, Brooks Sayre

AU - Schwab, T. R.

AU - Zimmerman, R. S.

AU - Heublein, D. M.

AU - Jiang, N. S.

AU - Burnett, John C Jr.

PY - 1986

Y1 - 1986

N2 - Studies done in vitro have demonstrated that atrial natriuretic peptide (ANP) antagonizes angiotensin II-mediated contraction of vascular smooth muscle. The present studies were designed to examine the in vivo actions of ANP in acute angiotensin II-mediated hypertension. The cardiovascular, renal, and hormonal effects of intravenous ANP were evaluated in anesthetized normotensive (n = 6) and hypertensive (n = 6) dogs. In both groups, ANP (3.0 μg/kg bolus, 0.3 μg/kg/min continuous infusion) reduced arterial pressure and cardiac output without changing systemic vascular resistance. ANP specifically reduced renal vascular resistance and increased sodium excretion. The natriuresis observed was greater in hypertensive than in normotensive dogs. This occurred without a significant change in glomerular filtration rate or aldosterone. The ANP-mediated reduction in arterial pressure was associated with an increase in circulating arginine vasopressin and catecholamines but not in renin. These studies demonstrate that (1) ANP-mediated hypotension results from a reduction in cardiac output without changing systemic vascular resistance, (2) ANP acts as a specific renal vasodilator, (3) ANP-mediated natriuresis can occur without alteration in glomerular filtration rate or aldosterone, and (4) ANP specifically inhibits the release of renin without inhibiting the release of other circulating vasocontrictors.

AB - Studies done in vitro have demonstrated that atrial natriuretic peptide (ANP) antagonizes angiotensin II-mediated contraction of vascular smooth muscle. The present studies were designed to examine the in vivo actions of ANP in acute angiotensin II-mediated hypertension. The cardiovascular, renal, and hormonal effects of intravenous ANP were evaluated in anesthetized normotensive (n = 6) and hypertensive (n = 6) dogs. In both groups, ANP (3.0 μg/kg bolus, 0.3 μg/kg/min continuous infusion) reduced arterial pressure and cardiac output without changing systemic vascular resistance. ANP specifically reduced renal vascular resistance and increased sodium excretion. The natriuresis observed was greater in hypertensive than in normotensive dogs. This occurred without a significant change in glomerular filtration rate or aldosterone. The ANP-mediated reduction in arterial pressure was associated with an increase in circulating arginine vasopressin and catecholamines but not in renin. These studies demonstrate that (1) ANP-mediated hypotension results from a reduction in cardiac output without changing systemic vascular resistance, (2) ANP acts as a specific renal vasodilator, (3) ANP-mediated natriuresis can occur without alteration in glomerular filtration rate or aldosterone, and (4) ANP specifically inhibits the release of renin without inhibiting the release of other circulating vasocontrictors.

UR - http://www.scopus.com/inward/record.url?scp=0022894818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022894818&partnerID=8YFLogxK

M3 - Article

C2 - 2949886

AN - SCOPUS:0022894818

VL - 59

SP - 663

EP - 667

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 6

ER -